2.69
+0.155(+6.11%)
Currency In USD
| Previous Close | 2.54 |
| Open | 2.54 |
| Day High | 2.76 |
| Day Low | 2.54 |
| 52-Week High | 12.51 |
| 52-Week Low | 1.64 |
| Volume | 10.56M |
| Average Volume | 17.3M |
| Market Cap | 973.39M |
| PE | -2.22 |
| EPS | -1.21 |
| Moving Average 50 Days | 2.32 |
| Moving Average 200 Days | 4.53 |
| Change | 0.16 |
If you invested $1000 in Iovance Biotherapeutics, Inc. (IOVA) 10 years ago, it would be worth $438.83 as of August 24, 2025 at a share price of $2.69. Whereas If you bought $1000 worth of Iovance Biotherapeutics, Inc. (IOVA) shares 5 years ago, it would be worth $93.11 as of August 24, 2025 at a share price of $2.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
GlobeNewswire Inc.
Aug 18, 2025 8:15 PM GMT
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
GlobeNewswire Inc.
Jul 24, 2025 8:05 PM GMT
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patient
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
GlobeNewswire Inc.
Jul 15, 2025 11:30 AM GMT
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies